Cell therapy for lung disease

European Respiratory Review

Volumn 26, Issue 144, 2017, Pages

  Geiger, Sabine ^a   Hirsch, Daniela ^a   Hermann, Felix G ^a  

^a Apceth GmbH and Co KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOXIN A; MACROPHAGE INFLAMMATORY PROTEIN 2; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DNA STRAND BREAKAGE; ENZYME INHIBITION; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INDUCED PLURIPOTENT STEM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG EMPHYSEMA; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CONVALESCENCE; LUNG; LUNG DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; TREATMENT OUTCOME;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; LUNG; LUNG DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; RECOVERY OF FUNCTION; REGENERATION; TREATMENT OUTCOME;

EID: 85021672978     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0044-2017     Document Type: Article

References (47)

1. Fröhlich E, Mercuri A, Wu S, et al. Measurements of deposition, lung surface area and lung fluid for simulation of inhaled compounds. Front Pharmacol 2016; 7: 181.
2. Tata PR, Rajagopal J. Plasticity in the lung: making and breaking cell identity. Development 2017; 144: 755–766.
3. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015; 2015: 394917.
4. Nurkovic J, Dolicanin Z, Mustafic F, et al. Mesenchymal stem cells in regenerative rehabilitation. J Phys Ther Sci 2016; 28: 1943–1948.
5. Weiss DJ. Concise review: current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells 2014; 32: 16–25.
6. Barry FP, Murphy JM, English K, et al. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 2005; 14: 252–265.
7. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013; 13: 392–402.
8. Prockop DJ, Oh JY. Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem 2012; 113: 1460–1469.
9. Shi Y, Hu G, Su J, et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010; 20: 510–518.
10. Kennelly H, Mahon BP, English K. Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD. Sci Rep 2016; 6: 38207.
11. Kim YS, Kokturk N, Kim JY, et al. Gene profiles in a smoke-induced COPD mouse lung model following treatment with mesenchymal stem cells. Mol Cells 2016; 39: 728–733.
12. Song L, Guan XJ, Chen X, et al. Mesenchymal stem cells reduce cigarette smoke-induced inflammation and airflow obstruction in rats via TGF-β1 signaling. COPD 2014; 11: 582–590.
13. Gu W, Song L, Li XM, et al. Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci Rep 2015; 5: 8733.
14. Li X, Zhang Y, Liang Y, et al. iPSC-derived mesenchymal stem cells exert SCF-dependent recovery of cigarette smoke-induced apoptosis/proliferation imbalance in airway cells. J Cell Mol Med 2017; 21: 265–277.
15. Weiss DJ, Casaburi R, Flannery R, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013; 143: 1590–1598.
16. de Oliveira HG, Cruz FF, Antunes MA, et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema: a phase I clinical trial. Stem Cells Transl Med 2017; 6: 962–969.
17. Curley GF, Jerkic M, Dixon S, et al. Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent Escherichia coli-induced acute respiratory distress syndrome. Crit Care Med 2017; 45: e202–e212.
18. Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007; 4: e269.
19. Saito S, Nakayama T, Hashimoto N, et al. Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. Am J Pathol 2011; 179: 1088–1094.
20. Fang X, Abbott J, Cheng L, et al. Human mesenchymal stem (stromal) cells promote the resolution of acute lung injury in part through lipoxin A4. J Immunol 2015; 195: 875–881.
21. Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo. Mediators Inflamm 2016; 2016: 2347938.
22. Hu S, Li J, Xu X, et al. The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo. Stem Cell Res Ther 2016; 7: 66.
23. Xiang B, Chen L, Wang X, et al. Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci 2017; 18.
24. Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015; 3: 24–32.
25. Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014; 15: 39.
26. Cahill EF, Kennelly H, Carty F, et al. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-induced pulmonary fibrosis. Stem Cells Transl Med 2016; 5: 1307–1318.
27. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407–8411.
28. Moodley Y, Atienza D, Manuelpillai U, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009; 175: 303–313.
29. Reddy M, Fonseca L, Gowda S, et al. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone. Int J Stem Cells 2016; 9: 192–206.
30. Lan YW, Choo KB, Chen CM, et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther 2015; 6: 97.
31. Li X, An G, Wang Y, et al. Anti-fibrotic effects of bone morphogenetic protein-7-modified bone marrow mesenchymal stem cells on silica-induced pulmonary fibrosis. Exp Mol Pathol 2017; 102: 70–77.
32. Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 1013–1018.
33. Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013; 11: 171.
34. World Health Organization. The Top 10 Causes of Death. www.who.int/mediacentre/factsheets/fs310/en/ Date last accessed: March 16, 2017. Date last updated: January 2017.
35. Lomas DA. Does protease-antiprotease imbalance explain chronic obstructive pulmonary disease? Ann Am Thorac Soc 2016; 13: Suppl. 2, S130–S137.
36. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365.
37. Bergin DA, Hurley K, McElvaney NG, et al. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent. Arch Immunol Ther Exp 2012; 60: 81–97.
38. 1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats. Clin Exp Immunol 2015; 179: 161–172.
39. Canning BJ, Wright JL. Animal models of asthma and chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008; 21: 695.
40. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307: 2526–2533.
41. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012; 122: 2731–2740.
42. Butt Y, Kurdowska A, Allen TC. Acute lung injury: a clinical and molecular review. Arch Pathol Lab Med 2016; 140: 345–350.
43. Katzenstein AL, ed. Acute Lung Injury Patterns: Diffuse Alveolar Damage and Bronchitis Obliterans Organizing Pneumonia. 4th Edn. Philadelphia, Saunders Elsevier, 2006.
44. Maderna P, Cottell DC, Toivonen T, et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 2010; 24: 4240–4249.
45. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187: 751–760.
46. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005; 33: 9–13.
47. Chanda D, Kurundkar A, Rangarajan S, et al. Developmental reprogramming in mesenchymal stromal cells of human subjects with idiopathic pulmonary fibrosis. Sci Rep 2016; 6: 37445.